Evidence map›Paper›PMID 33778448›Full record

ArticleCJC open2021

Von Willebrand Factor and ADAMTS13 as Predictors of Adverse Outcomes in Patients With Nonvalvular Atrial Fibrillation.

Waldemar E Wysokinski, Rowlens M Melduni, Naser M Ammash, Danielle T Vlazny, Ewa Konik, Rayya A Saadiq, Izabela Gosk-Bierska, Joshua Slusser, Diane Grill, Robert D McBane

Open access · goldAbstract read
In one paragraph

Article in CJC open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Waldemar E WysokinskiDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Rowlens M MelduniDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Naser M AmmashDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Danielle T VlaznyDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Ewa KonikDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Rayya A SaadiqDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Izabela Gosk-BierskaDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Joshua SlusserDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Diane GrillDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Robert D McBaneDivision of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, Rochester, Minnesota, USA.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVon Willebrand factor (VWF) elevation correlates with the left atrial blood stasis in nonvalvular atrial fibrillation (NVAF). However, the long-term impact of elevated VWF in patients with NVAF is not well established.

methodsTo assess the impact of VWF and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in conjunction with echocardiographic measures of left atrium blood stasis on clinical outcomes, 414 NVAF prospectively recruited (October 4, 2007, to April 27, 2009) patients were followed for 3 years. VWF antigen, VWF activity, ADAMTS13 activity, and echocardiographic findings were assessed at baseline. Thromboembolism (TE) (stroke/transient ischemic attack (TIA)), myocardial infarction, or TE of other locations), major bleeding, clinically relevant nonmajor bleeding, and all-cause mortality were assessed by clinical follow-up, questionnaire, or telephone communication.

resultsAmong 374 patients (mean age, 63.4 ± 12.7 years; 25% females) who had complete follow-up data, there were 33 TE in 32 patients (8.6%), 18 deaths (5.1%), and 33 bleeding events (21 major bleeding and 12 clinically relevant nonmajor bleeding) in 25 patients (6.7%). VWF antigen was predictive of TE in the univariate examination (hazard ratio [HR]: 1.007, 95% confidence interval [CI]: 1.002, 1.013,

conclusionsAmong patients with NVAF, VWF is an independent predictor of poor outcomes including death and a composite of death and TE. As such, VWF measure may help identify high-risk patients and provide further stratification beyond CHA

Identifiers

PMID33778448
PMCPMC7984998
OpenAlexW3100930241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.